Literature DB >> 31984161

Management of Paroxysmal Sympathetic Hyperactivity with Dexmedetomidine and Propranolol Following Traumatic Brain Injury in a Pediatric Patient.

Joshua W Branstetter1,2, Kelsey L Ohman1,2, Donald W Johnson1,2, Brian W Gilbert3.   

Abstract

We report a case of pharmacologic management of pediatric paroxysmal sympathetic hyperactivity (PSH) in a patient who experienced symptomatic resolution with dexmedetomidine and propranolol. Following a blunt traumatic subdural hematoma and diffuse axonal injury, an 8-year-old male developed PSH on approximately day 5 of the hospitalization. PSH symptoms identified in this patient were hyperthermia, tachycardia, posturing, and hypertension with associated elevations in intracranial pressure. Episodes of PSH continued to be observed despite appropriate titration of opiates, sedatives, and traditional blood pressure management. Dexmedetomidine and propranolol were subsequently initiated to attenuate acute episodes of PSH. A reduction in sedative requirements and improvement in symptoms followed, which facilitated successful extubation. The combination of propranolol and dexmedetomidine was followed by a decrease in the frequency and severity of acute episodes of PSH. After utilization of multiple treatment modalities to control PSH episodes in our patient, propranolol and dexmedetomidine may have helped attenuate PSH signs and symptoms. © Thieme Medical Publishers.

Entities:  

Keywords:  dexmedetomidine; paroxysmal sympathetic hyperactivity; pediatrics; propranolol; traumatic brain injury

Year:  2019        PMID: 31984161      PMCID: PMC6978171          DOI: 10.1055/s-0039-1698758

Source DB:  PubMed          Journal:  J Pediatr Intensive Care        ISSN: 2146-4626


  25 in total

1.  Paroxysmal sympathetic hyperactivity after traumatic brain injury: clinical and prognostic implications.

Authors:  Juan Francisco Fernandez-Ortega; Miguel Angel Prieto-Palomino; Manuel Garcia-Caballero; Juan Luis Galeas-Lopez; Guillermo Quesada-Garcia; Ian J Baguley
Journal:  J Neurotrauma       Date:  2012-02-22       Impact factor: 5.269

2.  Diagnosing dysautonomia after acute traumatic brain injury: evidence for overresponsiveness to afferent stimuli.

Authors:  Ian J Baguley; Melissa T Nott; Shameran Slewa-Younan; Roxana E Heriseanu; Iain E Perkes
Journal:  Arch Phys Med Rehabil       Date:  2009-04       Impact factor: 3.966

3.  Paroxysmal sympathetic hyperactivity after acquired brain injury: consensus on conceptual definition, nomenclature, and diagnostic criteria.

Authors:  Ian J Baguley; Iain E Perkes; Juan-Francisco Fernandez-Ortega; Alejandro A Rabinstein; Giuliano Dolce; Henk T Hendricks
Journal:  J Neurotrauma       Date:  2014-07-28       Impact factor: 5.269

4.  Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition.

Authors:  Nancy Carney; Annette M Totten; Cindy O'Reilly; Jamie S Ullman; Gregory W J Hawryluk; Michael J Bell; Susan L Bratton; Randall Chesnut; Odette A Harris; Niranjan Kissoon; Andres M Rubiano; Lori Shutter; Robert C Tasker; Monica S Vavilala; Jack Wilberger; David W Wright; Jamshid Ghajar
Journal:  Neurosurgery       Date:  2017-01-01       Impact factor: 4.654

5.  Diencephalic seizures: responsiveness to bromocriptine and morphine.

Authors:  D E Bullard
Journal:  Ann Neurol       Date:  1987-06       Impact factor: 10.422

6.  Dexmedetomidine for refractory adrenergic crisis in familial dysautonomia.

Authors:  Ryan C Dillon; Jose-Alberto Palma; Christy L Spalink; Diana Altshuler; Lucy Norcliffe-Kaufmann; David Fridman; John Papadopoulos; Horacio Kaufmann
Journal:  Clin Auton Res       Date:  2016-10-17       Impact factor: 4.435

7.  Paroxysmal Sympathetic Hyperactivity After Severe Traumatic Brain Injury in Children: Prevalence, Risk Factors, and Outcome.

Authors:  Tariq O Alofisan; Yasser A Algarni; Ibrahim M Alharfi; Michael R Miller; Tanya Charyk Stewart; Douglas D Fraser; Janice A Tijssen
Journal:  Pediatr Crit Care Med       Date:  2019-03       Impact factor: 3.624

8.  Autonomic nervous system responses during sedative infusions of dexmedetomidine.

Authors:  Charles W Hogue; Pekka Talke; Phyllis K Stein; Charles Richardson; Peter P Domitrovich; Daniel I Sessler
Journal:  Anesthesiology       Date:  2002-09       Impact factor: 7.892

9.  Effect of dexmedetomidine, a selective and potent alpha 2-agonist, on cerebral blood flow and oxygen consumption during halothane anesthesia in dogs.

Authors:  B R Karlsson; M Forsman; O K Roald; M S Heier; P A Steen
Journal:  Anesth Analg       Date:  1990-08       Impact factor: 5.108

Review 10.  Critical care management of severe traumatic brain injury in adults.

Authors:  Samir H Haddad; Yaseen M Arabi
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2012-02-03       Impact factor: 2.953

View more
  2 in total

1.  Effect Evaluation of Dexmedetomidine Intravenous Anesthesia on Postoperative Agitation in Patients with Craniocerebral Injury by Magnetic Resonance Imaging Based on Sparse Reconstruction Algorithm.

Authors:  Xue Feng; Binbin Zhao; Yongqiang Wang
Journal:  Contrast Media Mol Imaging       Date:  2022-06-23       Impact factor: 3.009

Review 2.  The neuroprotective effect of dexmedetomidine and its mechanism.

Authors:  Yijun Hu; Hong Zhou; Huanxin Zhang; Yunlong Sui; Zhen Zhang; Yuntao Zou; Kunquan Li; Yunyi Zhao; Jiangbo Xie; Lunzhong Zhang
Journal:  Front Pharmacol       Date:  2022-09-20       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.